The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A.

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 1943-1950

  Kupčová, Viera ^a   Šperl, Jan ^b   Pannier, Anne ^c   Jordan, Paul ^c   Dougherty, Frank C ^c   Reigner, Bruno ^c  

^a Derer 's University Hospital Slovakia   (Slovakia)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Chronic kidney disease; Continuous erythropoietin receptor activator (C.E.R.A.); Pharmacodynamics; Pharmacokinetics; Renal anaemia; Severe hepatic impairment

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ARTIFACT; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG TOLERABILITY; EOSINOPHIL COUNT; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; FOLLOW UP; HEMATOCRIT; HEMATURIA; HUMAN; LIVER DISEASE; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPHIL COUNT; PHARMACOLOGICAL PARAMETERS; RETICULOCYTE COUNT; SCREENING; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; VITAL SIGN;

ADOLESCENT; ADULT; AGED; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETICULOCYTES;

EID: 47949114165     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802176467     Document Type: Article

References (22)

1. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989;73:90-9
2. Macdougall IC. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002;17(Suppl 5):66-70
3. Xue JL, St Peter WL, Ebben JP, et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002;40:1153-61
4. Hörl WH, Macdougall I, Rossert J, et al. Predialysis survey on anemia management: patient referral. Am J Kidney Dis 2003;41:49-61
5. Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-ii47
6. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S11-S145
7. Jones M, Ibels L, Schenkel B, et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004;65:757-67
8. Gouva C, Nickolopoulos P, Ioannidis JPA, et al. Treating anaemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004;66:753-60
9. Dean BB, Dylan M, Gano Jr A, et al. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005;21:981-7
10. Lu WX, Jones-Burton C, Zhan M, et al. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract 2005;101:79-86
11. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-5
12. Macdougall IC, Bailon P, Tare N, et al. CERA (continuous erythropoiesis receptor activator) for the treatment of renal anemia: an innovative agent with unique receptor binding characteristics and prolonged serum half-life. J Am Soc Nephrol 2003;14:769A[Abstract SU-PO1063]
13. Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007;16:1649-61
14. Levin NW, Fishbane S, Valdés Cañedo F, et al. on behalf of the MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-21
15. Sulowicz W, Locatelli F, Ryckelynck J-P, et al. on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-46
16. Chapel SH, Veng-Pedersen P, Schmidt RL, et al. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 2001;29:425-31
17. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-74
18. Al-Huniti NH, Widness JA, Schmidt RL, et al. Pharmacokinetic/ pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. J Pharmacol Exp Ther 2004;310:202-8
19. Veng-Pedersen P, Chapel S, Al-Huniti NH, et al. Pharmacokinetic tracer kinetic analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 2004;25:149-56
20. Glaspy J, Henry D, Patel R, et al. Darbepoetin Alfa 20010162 Study Group. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9
21. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
22. Skluzacek PA, Szewc RG, Nolan 3rd CR, et al. Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003;42:1169-76